Cargando…

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population

AIMS: This study is aimed at investigating the eligibility in a real-world heart failure population for the DAPA-HF (testing dapagliflozin) and EMPEROR-reduced (testing empagliflozin) trials, comparing the eligible real-world patients to trial participants and to characterize the noneligible patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Håkansson, Erik, Norberg, Helena, Själander, Sara, Lindmark, Krister
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720587/ https://www.ncbi.nlm.nih.gov/pubmed/35024052 http://dx.doi.org/10.1155/2021/1894155

Ejemplares similares

Prevalence and treatment of diabetes and pre-diabetes in a real-world heart failure population: a single-centre cross-sectional study
por: Håkansson, Erik, et al.
Publicado: (2022)

Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study
por: Norberg, Helena, et al.
Publicado: (2018)

Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2022)

Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real‐world heart failure cohort
por: Beles, Monika, et al.
Publicado: (2023)

Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population
por: Jonsson, Anna, et al.
Publicado: (2018)

Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan
por: Holmlund, Lena, et al.
Publicado: (2019)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2021)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
por: Shi, Zepeng, et al.
Publicado: (2022)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Comparison of creatinine‐based methods for estimating glomerular filtration rate in patients with heart failure
por: Jonsson, Anna, et al.
Publicado: (2020)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
por: Simpson, Joanne, et al.
Publicado: (2019)

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
por: Norberg, Helena, et al.
Publicado: (2019)

Recurrent heart failure hospitalizations increase the risk of cardiovascular and all‐cause mortality in patients with heart failure in Sweden: a real‐world study
por: Lindmark, Krister, et al.
Publicado: (2021)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Current Status of Dapagliflozin in Congestive Heart Failure
por: Palandurkar, Gopal, et al.
Publicado: (2022)

Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic
por: Lindmark, Krister, et al.
Publicado: (2020)

Characteristics and management of very elderly patients with heart failure: a retrospective, population cohort study
por: Olofsson, Mona, et al.
Publicado: (2022)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study
por: Norberg, Helena, et al.
Publicado: (2020)

Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry
por: Oh, Jaewon, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden
por: Lindmark, Krister, et al.
Publicado: (2019)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta, Manasvi, et al.
Publicado: (2021)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
por: Kowalska, Klaudia, et al.
Publicado: (2021)

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
por: Biegus, Jan, et al.
Publicado: (2022)

Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients
por: Kim, Soo-Jin, et al.
Publicado: (2022)

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
por: Gotzmann, Michael, et al.
Publicado: (2023)

Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Diabetes and treatment of chronic heart failure in a large real‐world heart failure population
por: Radhoe, Sumant P., et al.
Publicado: (2021)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world
por: Ciprandi, Giorgio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1rib836240pquc2enh96pkreet